Thuenthkin Anbelos

Mesothelioma Doctor, Advocate and Volunteers Recognized by the Mesothelioma Applied Research Foundation

The Mesothelioma Applied Research Foundation will present three awards at the International Symposium on Malignant Mesothelioma on Friday, June 26th in Washington, DC. This year's award recipients include Dr. Robert Taub, Terry Lynch, and Craig & Shelly Kozicki. Galvanizing our community's tremendous diversity, talent, strength and knowledge is the key to developing more effective mesothelioma treatments and, one day, the cure. I am proud to be a part of this vibrant and dedicated community and I applaud this year's award recipients

Santa Barbara, CA (PRWEB) June 22, 2009 -- To recognize the extensive studies, long hours and personal investment of those involved in eradicating mesothelioma, the Mesothelioma Applied Research Foundation will present three awards at the Gala Celebration of Hope on Friday June 26th, day two of the International Symposium on Malignant Mesothelioma, to be held Thursday, June 25th through Saturday, June 27th at the Omni Shoreham, in Washington, DC.

"Galvanizing our community's tremendous diversity, talent, strength and knowledge is the key to developing more effective mesothelioma treatments and, one day, the cure. I am proud to be a part of this vibrant and dedicated community and I applaud this year's award recipients," says Dr. Nicholas Vogelzang, Chairman of the Meso Foundation's Board of Directors.

The Pioneer Award emphasizes the contributions of Dr. Robert Taub, MD PhD, whose treatment protocols and vision have shown remarkable results and have been the basis of hope for many mesothelioma patients; The Bruce Vento Hope Builder Award, named for the late Minnesota Congressman who died from mesothelioma in 2000, acknowledges the support and initiatives of Terry Lynch, International Vice President, Political & Legislative Director and Health Hazard Administrator of the International Association of Heat and Frost Insulators and Allied Workers; and The Volunteer of the Year Award honors Craig and Shelly Kozicki for being an inspiration to the mesothelioma community through their continued dedication in raising research funds and providing support and hope to others faced with mesothelioma. Craig, who had been diagnosed with mesothelioma in 1998, died in May of this year.

The Symposium, organized annually by the Mesothelioma Applied Research Foundation, will highlight the latest advances in research and treatment for patients and caregivers, offer psychosocial support to them as well as those who have lost someone to the disease, and provide all who are intent on eradicating the vicious and terminal effects of this tragic cancer with significant advocacy and volunteer opportunities. The three-day conference is dedicated to mesothelioma science, advocacy, and community.

Those wishing to attend can register for the symposium and get additional information on the Meso Foundation's website.

The Mesothelioma Applied Research Foundation is the national non-profit dedicated to finding a cure for mesothelioma by funding mesothelioma research, providing mesothelioma patients support services and participating in federal mesothelioma advocacy. Visit www.curemeso.org for more information.

CONTACT INFORMATION
Maja Belamaric
Mesothelioma Applied Research Foundation (Meso Foundation)
(805) 456-7272

# posted by Thuenthkin Anbelos : 12:39 AM  0 Comments

Asbestos Fiber Links With The Human Cells

2009-06-07 (WiredPRNews.com - Mesothelioma Asbestos, Press Releases)Dallas, TX: The Ohio University team of scientists are trying to establish individual bondage of the asbestos fiber and the human cell. There are two major forms , under their observation. Both of these forms are linked with the exposure of asbestos. Those people, who work at the asbestos job sites are the main targets. The onset takes place due to the inhalation or the swallowing of the tiny, microscopic fibers. These two forms of diseases are:

Asbestosis: It's a chronic respiratory disease. The attack is on the respiratory track, and it proves fatal. No cure has been discovered so far.

Mesothelioma: This infection can be of the lungs, chest or of the heart. There is no cure for this disease, too, and the prognosis is of six to twelve months, once the symptoms appear.

Asbestos occurs in six different forms, in nature, all these forms have proved deadly. Due to its qualities of durability and high resistance, it was widely used in a number of industries, till the first half of the last century. By the year 1940, it was totally banned in about forty countries of Europe and the United States, but asbestos is still present inn the manufactured stuff and is considered dangerous to human life. The breaking of the asbestos-related goods and the demolition of old buildings and structures, spread the dust and the fiber into the open atmosphere.

The team of scholars is using the 'Atomic Force Microscopy' to study, as to how a single fiber, during the exposure, after inhaling, clings itself with the cell surface of the lining of the organs.

One of the research candidates, has described this study as a type of 'braille work between the two ends of this bondage and says that the scientists will feel and observe, how the asbestos links with the human cells.

The U.S, Department of labor estimates about 1.3 million people will be the target of this disease in the coming years. This is the number of the labor exposed to asbestos, from 1960s up to '80s.

# posted by Thuenthkin Anbelos : 2:14 PM  0 Comments

United Medical Brokers Launches Website Dedicated to Purchase and Sale of Medical Related Businesses and Real Estate

New York, NY, April 01, 2009 -- United Medical Brokers announced its nationwide launch today from its corporate headquarters. United Medical Brokers www.unitedmedicalbrokers.com is now offering nationwide brokerage services for buyers and sellers of medical practices, medical related businesses, and medical related real estate.

The company is a division of Bridge Business and Property Brokers which is a leading business brokerage firm. Bridge was recently named to the INC 500 list of fastest growing companies. Currently there is no firm that offers nationwide support for buyers and sellers of medical related businesses.

United will maintain medical transaction specialists at each of its offices to support the diverse needs of medical business clients. The Managing Partner of the firm is Robert Flynn who spent most of his career with the publicly traded $3 billion London based Cookson Group plc as a senior executive; he brings decades of transaction related experience to the company.

The firm's growth strategy includes affiliations with leading national providers of medical business related services that are positioned to quickly identify medical related transaction opportunities. Prudential Real Estate has joined as an affiliate to serve the medical related real estate needs of United Medical Broker clients across the United States. Priority Leasing is also affiliated to provide medical equipment financing services.

"I am very excited about this expansion of our successful brokerage model. Medical related businesses continue to prosper during these difficult economic times. The long-term fundamentals look exceptionally positive and we are positioned to capitalize on them. Near term the health related policies being planned and executed by the new presidential administration will create further demand for our services," said A.J. Caro, founder of Bridge Business and Property Brokers.

Bridge's President also voiced excitement stating, "The launch of this division shows our commitment to dominating the marketplace by offering expert services to specific vertical markets."

For more information visit the company website at www.unitedmedicalbrokers.com

Contact Information
United Medical Brokers
Robert A. Flynn
401-744-0320
rflynn@unitedmedicalbrokers.com
unitedmedicalbrokers.com

# posted by Thuenthkin Anbelos : 12:01 PM  0 Comments

Diesel Users Suffer More Lung Cancer; a Simple Solution is to Hand from ChemEcol and VEPower

Those who work with and at close proximity to diesel engines, especially lorry drivers, are at a higher risk of cancer according to a recent US study. This is on top of the elevated risk of "heart disease and stroke, possibly resulting from enhanced coagulation and arterial thrombosis" such exposure gives. The good news is that a British company has developed a fuel technology that is seen to significantly reduce ultra fine particulate emissions by as much as 45%.

Welwyn Garden City, United Kingdom, March 28, 2009 -- Truckers endure such grave risks as lung cancers, heart disease and stroke all the time they run their engines. But it's not just the lorry drivers who are at risk. The American study also saw that those working with the and near trucks (fork truck drivers, warehousemen, mechanics, and even office workers) are at elevated risk from these killers. Why?

Diesel exhaust carries particulate matter; this is what colours it smoky black. Particulates are both created by and carriers of toxic substances called polycyclic aromatic hydrocarbons (PAHs). Many of these are known to be particularly carcinogenic, mutagenic. Some of these particles are small enough (100nm or less) to be classified as nanoparticles. These have been found to become distributed around the body via the blood supply once inhaled with notable deposits being found in the liver and heart. If ingested (when particles have settled on food or in drink) they will also pass into the gastro-intestinal tract (4).

It's not just haulage workers and their colleagues who are at risk. Black carbon (again, part of the exhaust) exposure in city children has been shown to reduce development in terms of intelligence (5). The particulate matter we have been looking at is known also to exacerbate respiratory complaints, allergies such as asthma and may agitate some skin complaints also. Some studies have found that certain particulate constituents can be carcinogenic on the skin as well as when inhaled (6).

ChemEcol (UK) Ltd. makes the combustion enhancer Additone. The technology has been developed as a response to the grave threats posed by vehicle exhaust pollution. ChemEcol's products are not based on metallic catalysts, nano-technology or otherwise, as such would counteract the goal of reducing particulate pollutant emissions (the metallic particles would be exhausted along with the other emissions). In fact this technology is based on pure hydrocarbon formulations, maintaining the physical properties of the diesel.

ChemEcol's patented technology modifies the processes of fuel combustion inside the engine, reducing the particulates produced at the most fundamental level. This has a beneficial side-effect of reducing fuel consumption as the PAHs otherwise produced can be considered to be wasted fuel. This change then reduces CO2 emissions and costs by an average of 3%.

VEPower Ltd markets ChemEcol's product. They can be reached at ChemEcol on +44 (0) 1707 330400, at www.chemecol.net and neil@chemecol.net.

Contact Information
ChemEcol Ltd
Nel Faulkner
+44 (0) 20 3286 8771
neil@chemecol.net
www.chemecol.net


 

# posted by Thuenthkin Anbelos : 10:09 AM  0 Comments

 Allina Hospitals & Clinics Responds to Attorney General's Suit

MINNEAPOLIS - January 2009 -- In response to a lawsuit filed today by the Minnesota Attorney General's Office, Allina Hospitals & Clinics made the following statement:

"Allina Hospitals & Clinics is surprised by the Attorney General's action today. Allina had been analyzing various proposals to modify MedCredit's interest rate structure for some time, and prior to the filing of this suit, Allina had made the decision to reduce the interest rate on all current and future MedCredit accounts to eight percent, regardless of the size of the balance. Allina communicated this to the Attorney General in December of 2008. Allina believes that this new rate structure is in the best interests of our patients who would benefit from the ability to pay their medical bills over time.

"While Allina believes the new rate of eight percent is appropriate going forward, it should be noted that the previous rate structure, which included a sliding interest rate scale based on the balance due, was fully consistent with Minnesota law, and was clearly communicated to all patients who participated in the program. The program is considered "open-ended credit," meaning that patients can use the program on an ongoing basis for subsequent care. The rates previously charged by Allina are consistent with Minnesota law for this type of credit.

Allina believes that MedCredit remains a valuable tool to help some patients pay their medical bills and that it may be a better alternative to financing such debt through a credit card, which may charge a much higher interest rate. Allina does not deny care to anyone based on inability to pay, and works with patients to help ensure they receive all possible forms of assistance in paying their medical bills, including free care or government assistance programs. Allina offers free care to individuals and families whose income is less that 275 percent of Federal poverty guidelines.

"Allina believes the allegations contained in the complaint are without merit and that the MedCredit program is fully compliant with the law. Allina looks forward to discussing this matter further with the Attorney General, and bringing it to a timely resolution."

Allina Hospitals & Clinics is a not-for-profit health care system of hospitals, clinics and other patient care services that provides exceptional care to communities throughout Minnesota and western Wisconsin and employs more than 22,000 people. Allina Hospitals & Clinics facilities, services and jobs can be found online at www.allina.com.

Contacts

Allina Hospitals & Clinics
David Kanihan, 612-262-4986
david.kanihan@allina.com
Cell: 612-867-2845

# posted by Thuenthkin Anbelos : 5:22 PM  0 Comments

LegalView Updates Avandia Information Portal with News That Avandia May be More Dangerous Than Similar Drugs

LegalView recently relaunched is Avandia information portal with updated news that the type 2 diabetes drug has more safety risks than drugs of a similar nature. A study from U.S. researchers was published evaluating the dangers of the diabetes drugs and found Avandia as riskier for patients than Actos.

Denver, CO, December 02, 2008 -- LegalView.com, the number one resource for everything and anything legal on the Web, recently announced an update to its Avandia information portal with news that the type 2 diabetes drug poses more safety risks to patients than similar drugs including Actos. According to a Reuters article published in November, the Avandia study as well as analysis has been conducted of the drugs and has found that of both Avandia and Actos, Avandia poses greater risks, especially among older-aged diabetic patients and that the risks include an increased chance of developing heart disease.

Individuals who consume Avandia and who are concerned about the Avandia side effects, which may potentially include early on-set osteoporosis as well as heart failure, according to the New England Journal of Medicine, may need to discuss discontinuing use of the drug with a medical professional. Additionally, contacting an experienced pharmaceutical and Avandia attorney who may be able to provide a free legal consultation as to the development of a potential Avandia class action lawsuit.

 Avandia was first introduced from GlaxoSmithKline in May 1999 and was prescribed to nearly 3 million type 2 diabetes sufferers. In 2007 a U.S. Food and Drug Administration (FDA) health advisory alert was issued regarding the discovery of the alleged link that Avandia patients may be at a greater risk for developing heart disease and heart failure, while also being more susceptible to broken bones and fractures due to a potential osteoporosis risk. Patients consuming the drug should speak with their physician as well as consider the development of litigation for the potential of earning monetary compensation.

LegalView has also made available information portals on several other topics ranging from information on traumatic brain injuries to other controversial pharmaceutical drugs such as Byetta and Ketek.

According to the Brain Injury Association of America, approximately 1.4 million Americans suffer from a traumatic brain injury each year. The condition has also been deemed the signature injury of the war in Iraq by news organizations and medical professionals. Additionally, thousands of individuals are not treated for their TBI condition, which could cause a worsening of the TBI side effects among patients. It is imperative that an individual who may have suffered from a TBI accident contact a medical professional regarding their potential condition.

Byetta (exenatide) from Amilyn Pharmaceuticals and Eli Lilly was released in 2005, however, the type 2 diabetes drug was allegedly under investigation by the FDA for the potential link to pancreatic inflammation among Byetta patients. In August 2008, approximately six individuals consuming the drug had developed acute pancreatitis and of the six, two had died. Patients of Byetta who are concerned about the potential dangers allegedly associated with the drug are advised to contact a Byetta law firm for more information.

Ketek, which has been available since 2004 from Sanofi-Aventis, has been allegedly linked to the development of liver damage among patients who have consumed the antibiotic that treats upper respiratory infections such as bronchitis and community acquired pneumonia. The FDA is also currently investigating the drug, but those who have been affected by the Ketek side effects are encouraged to contact a medical professional as well as a pharmaceutical attorney.

About LegalView:

LegalView.com is a public service brought to you by Legal WebTV Network, LLC, a Limited Liability Corporation created by a group of the nation's most highly respected law firms: Anapol Schwartz; Brent Coon and Associates; Burg Simpson; Cohen, Placitella and Roth; James F. Humphreys and Associates; Lopez McHugh; and Thornton and Naumes. For more information on the accomplishments and track records of LegalView.com's superior sponsoring law firms and to get in touch with LegalView attorneys, visit LegalView at www.LegalView.com.

Contact Information
LegalView
Katie Kelley
720-226-6613
press-releases@legalview.com
http://avandia.legalview.com

# posted by Thuenthkin Anbelos : 3:05 PM  0 Comments

LegalView Reports Results of a Breakthrough Study Investigating Link Between Genetic Predisposition and Developing Mesothelioma Cancer

LegalView informed readers to the results of a scientific investigation studying the potential link between genetic components and developing mesothelioma cancer. Scientists determined that genetic responses occurred after a specific type of asbestos was introduced to cells within the lining of the lungs.

Denver, CO, September 01 -- LegalView.com, the number one legal resource available on the Web, offered updated details on its mesothelioma information blog of an advanced scientific investigation studying the link between asbestos and genetics. Researchers, who found a genetic response to a specific type of asbestos known as crocidolite, published their findings in an August 2008 issue of BMC Genetics. The study, a first of its kind, used a methodology of exposing cells within the human lung lining to asbestos and then scientists watched the reaction and changes. The study offers mesothelioma victims a unprecedented look into how asbestos affects the human body. Victims were also provided with a gleam of progress on finding a cure for the condition, although the scientists stated more research is required.

Individuals who are suffering from an asbestos-related disease are advised to contact a mesothelioma law firm that can provide access to a wealth of knowledgeable mesothelioma attorneys. Because mesothelioma cancer is incurable and is commonly considered a preventable illness, discussing the details of a potential mesothelioma lawsuit with a mesothelioma lawyer may provide insight as to how monetary compensation could be awarded to aid in the costly medical bills associated with mesothelioma.

In their study, the researchers reported that asbestosis occurs in nearly 200,000 individuals each year with an additional 4,000 asbestos-related deaths occurring annually as well. Asbestos is a type of mineral that was mined for use in insulation because of its fire-retardant qualities and inexpensive production costs. However, inhaling asbestos fibers has led to a severe and incurable form of lung cancer known as mesothelioma. Millions of Americans may have been exposed to asbestos fibers during the 20th century, as asbestos was heavily mined and often used during the construction of buildings such as elementary schools, universities, hospitals, office buildings, homes and apartments.

In addition to mesothelioma information, LegalView houses a library of other legal issues potentially causing harm to everyday Americans. Also, due to the ongoing crisis among the pharmaceutical community, LegalView has provided updated information on several pharmaceutical drug's side effects and dangers. Among the drugs are Ketek as well as Levaquin and Cipro, both of the fluoroquinolone family.

Ketek (telithromycin) is an antibiotic used to treat conditions such as community-acquired pneumonia, bronchitis, sinusitis and other upper respiratory infections. The antibiotic is manufactured by Sanofi-Aventis and has been available to the market since 2004, however, since its release, the U.S. Food and Drug Administration (FDA) has reported nearly 20 deaths of individuals consuming the medication. The deaths all involved the development of liver damage among the patients who died as well as an additional 100 patients who also reported signs and symptoms of liver disease while taking Ketek. Those who have consumed Ketek and feel they exhibit any of the side effects commonly associated with liver disease, such as jaundice or yellowing of the skin, should seek medical assistance immediately. Additionally, it may be advisable for an individual to be involved with a Ketek class action lawsuit and contacting an experienced pharmaceutical lawyer will assist with any legal action necessary.

Levaquin (levofloxacin) and Cipro (ciprofloaxacin), similar to Ketek, are also antibiotics that treat bacterial infections such as bronchitis, although, in July 2008 the FDA gave all of the fluoroquinolone drugs an increased warning label known as the "black box" warning label, the harshest warning given by the FDA. The warning label was increased because the Levaquin and Cipro risks had been previously linked to tendon rupture among patients, according to several studies including one published in Clinical Rheumatology in February 2004. The black box warning is to encourage physicians to avoid prescribing these drugs to patients who may be at a greater risk for Achilles tendon rupture, including elderly patients.

LegalView provides a vast array of resources for individuals plagued by legal misfortune so that they may positively improve their situation and have the tools necessary to do so, including the recently updated Zimmer Durom cup information portal. The Zimmer Durom cup is an artificial hip component used during hip replacement surgery among patients. However, Zimmer Holdings, manufacturers of the product, recently halted the production of the hip socket after hundreds of doctors complained that the medical device was failing among patients. To learn more about the potential for a Zimmer Durom cup recall, visit the LegalView homepage at http://www.LegalView.com/.

About LegalView:

LegalView.com is a public service brought to you by Legal WebTV Network, LLC, a Limited Liability Corporation created by a group of the nation's most highly respected law firms: Anapol Schwartz; Brent Coon and Associates; Burg Simpson; Cohen, Placitella and Roth; James F. Humphreys and Associates; Lopez McHugh; and Thornton and Naumes. For more information on the accomplishments and track records of LegalView.com's superior sponsoring law firms and to get in touch with LegalView attorneys, visit LegalView at www.LegalView.com/.

Contact Information
LegalView
Katie Kelley
720-771-3246
press-releases@legalview.com
www.legalview.com

# posted by Thuenthkin Anbelos : 11:21 PM  0 Comments